|Symptoms||Vision loss, eye pain, mid-dilated pupil, redness of the eye, nausea|
|Usual onset||Gradual, or sudden|
|Risk factors||Increased pressure in the eye, family history, high blood pressure|
|Diagnostic method||Dilated eye examination|
|Differential diagnosis||Uveitis, trauma, keratitis, conjunctivitis|
|Treatment||Medication, laser, surgery|
The most common type is open-angle (wide angle, chronic simple) glaucoma, in which the drainage angle for fluid within the eye remains open, with less common types including closed-angle (narrow angle, acute congestive) glaucoma and normal-tension glaucoma.
Open-angle glaucoma develops slowly over time and there is no pain.
Peripheral vision may begin to decrease, followed by central vision, resulting in blindness if not treated.
Closed-angle glaucoma can present gradually or suddenly.
The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea.
Vision loss from glaucoma, once it has occurred, is permanent.
Eyes affected by glaucoma are referred to as being glaucomatous.
Risk factors for glaucoma include increasing age, high pressure in the eye, a family history of glaucoma, and use of steroid medication.
For eye pressures, a value of greater than 21 mmHg or 2.8 kPa is often used, with higher pressures leading to a greater risk.
However, some may have high eye pressure for years and never develop damage.
Conversely, optic nerve damage may occur with normal pressure, known as normal-tension glaucoma.
Diagnosis is by a dilated eye examination.
Often, the optic nerve shows an abnormal amount of cupping.
If treated early, it is possible to slow or stop the progression of disease with medication, laser treatment, or surgery.
The goal of these treatments is to decrease eye pressure.
A number of different classes of glaucoma medication are available.
Laser treatments may be effective in both open-angle and closed-angle glaucoma.
A number of types of glaucoma surgeries may be used in people who do not respond sufficiently to other measures.
Treatment of closed-angle glaucoma is a medical emergency.
About 70 million people have glaucoma globally.
The disease affects about 2 million people in the United States.
It occurs more commonly among older people.
Closed-angle glaucoma is more common in women.
Glaucoma has been called the "silent thief of sight," because the loss of vision usually occurs slowly over a long period of time.
Worldwide, glaucoma is the second-leading cause of blindness after cataracts.
Cataracts caused 51% of blindness in 2010, while glaucoma caused 8%.
The word "glaucoma" is from Ancient Greek glaukos, which means "shimmering."
In English, the word was used as early as 1587 but did not become commonly used until after 1850, when the development of the ophthalmoscope allowed people to see the optic nerve damage.
Signs and symptoms
Open-angle glaucoma is usually painless with no symptoms early in the disease process, thus screening via regular eye check-ups important.
About 10% of people with closed angles present with acute angle closure characterized by sudden ocular pain, seeing halos around lights, red eye, very high intraocular pressure (>30 mmHg), nausea and vomiting, suddenly decreased vision, and a fixed, mid-dilated pupil.
It is also associated with an oval pupil in some cases.
Acute angle closure is an emergency.
Opaque specks may occur in the lens in glaucoma, known as glaukomflecken.
Of the several causes for glaucoma, ocular hypertension (increased pressure within the eye) is the most important risk factor in most glaucomas, but in some populations, only 50% of people with primary open-angle glaucoma actually have elevated ocular pressure.
Ocular hypertension—an intraocular pressure above the traditional threshold of 21 mm Hg or even above 24 mm Hg—is not necessarily a pathological condition but it increases the risk of developing glaucoma.
One study found a conversion rate of 18% within 5 years, meaning less than 1 in 5 people with an elevated intraocular pressure will develop glaucomatous visual field loss over that period of time.
It is a matter of debate whether every person with an elevated intraocular pressure should receive glaucoma therapy; currently most ophthalmologists favor treatment of people with additional risk factors.
Open-angle glaucoma accounts for 90% of glaucoma cases in the United States.
Closed-angle glaucoma accounts for less than 10% of glaucoma cases in the United States, but as many as half of glaucoma cases in other nations (particularly East Asian countries).
No clear evidence indicates that vitamin deficiencies cause glaucoma in humans.
It follows, then, that oral vitamin supplementation is not a recommended treatment for glaucoma.
Many people of East Asian descent are prone to developing angle closure glaucoma due to shallower anterior chamber depths, with the majority of cases of glaucoma in this population consisting of some form of angle closure.
Positive family history is a risk factor for glaucoma.
The relative risk of having primary open-angle glaucoma (P.O.A.G.)
is increased about two- to four-fold for people who have a sibling with glaucoma.
Glaucoma, particularly primary open-angle glaucoma, is associated with mutations in several genes, including MYOC, ASB10, WDR36, NTF4, TBK1, and RPGRIP1, although most cases of glaucoma do not involve these genetic mutations.
Various rare congenital/genetic eye malformations are associated with glaucoma.
Angle closure-induced ocular hypertension and glaucomatous optic neuropathy may also occur with these anomalies, and has been modelled in mice.
Other factors can cause glaucoma, known as "secondary glaucoma", including prolonged use of steroids (steroid-induced glaucoma); conditions that severely restrict blood flow to the eye, such as severe diabetic retinopathy and central retinal vein occlusion (neovascular glaucoma); ocular trauma (angle-recession glaucoma); and inflammation of the middle layer of the pigmented vascular eye structure (uveitis), known as uveitic glaucoma.
The underlying cause of open-angle glaucoma remains unclear.
Several theories exist on its exact etiology.
However, the major risk factor for most glaucomas and the focus of treatment is increased intraocular pressure.
In open/wide-angle glaucoma, flow is reduced through the trabecular meshwork, due to the degeneration and obstruction of the trabecular meshwork, whose original function is to absorb the aqueous humor.
Loss of aqueous humor absorption leads to increased resistance and thus a chronic, painless buildup of pressure in the eye.
In close/narrow-angle, the iridocorneal angle is completely closed because of forward displacement of the final roll and root of the iris against the cornea, resulting in the inability of the aqueous fluid to flow from the posterior to the anterior chamber and then out of the trabecular network.
This accumulation of aqueous humor causes an acute increase in pressure and pain.
The inconsistent relationship of glaucomatous optic neuropathy with increased intraocular pressure has provoked hypotheses and studies on anatomic structure, eye development, nerve compression trauma, optic nerve blood flow, excitatory neurotransmitter, trophic factor, retinal ganglion cell/axon degeneration, glial support cell, immune system, aging mechanisms of neuron loss, and severing of the nerve fibers at the scleral edge.
Testing for glaucoma should include measurements of the intraocular pressure via tonometry, anterior chamber angle examination or gonioscopy, and examination of the optic nerve to look for any visible damage to it, or change in the cup-to-disc ratio and also rim appearance and vascular change.
A formal visual field test should be performed.
The retinal nerve fiber layer can be assessed with imaging techniques such as optical coherence tomography, scanning laser polarimetry, and/or scanning laser ophthalmoscopy (Heidelberg retinal tomogram).
Visual field loss is the most specific sign of the condition; however, it occurs later in the condition.
Owing to the sensitivity of all methods of tonometry to corneal thickness, methods such as Goldmann tonometry should be augmented with pachymetry to measure the central corneal thickness (CCT).
A thicker-than-average cornea can result in a pressure reading higher than the 'true' pressure whereas a thinner-than-average cornea can produce a pressure reading lower than the 'true' pressure.
Because pressure measurement error can be caused by more than just CCT (i.e., corneal hydration, elastic properties, etc.), it is impossible to 'adjust' pressure measurements based only on CCT measurements.
The frequency doubling illusion can also be used to detect glaucoma with the use of a frequency doubling technology perimeter.
Examination for glaucoma also could be assessed with more attention given to sex, race, history of drug use, refraction, inheritance and family history.
|What the test examines||Eye drops used||Physical contact with the eye||Procedure|
|Tonometry||Inner eye pressure||Maybe||Maybe||Eye drops may be used to numb the eye. The examiner then uses a tonometer to measure the inner pressure of the eye through pressure applied by a puff of warm air or a tiny tool.|
|Ophthalmoscopy (dilated eye examination)||Shape and color of the optic nerve||Yes||No||Eye drops are used to dilate the pupil. Using a small magnification device with a light on the end, the examiner can examine the magnified optic nerve.|
|Perimetry (visual field test)||Complete field of vision||No||No||The patient looks straight ahead and is asked to indicate when light passes the patient's peripheral field of vision. This allows the examiner to map the patient's field of vision.|
|Gonioscopy||Angle in the eye where the iris meets the cornea||Yes||Yes||Eye drops are used to numb the eye. A hand-held contact lens with a mirror is placed gently on the eye to allow the examiner to see the angle between the cornea and the iris.|
|Pachymetry||Thickness of the cornea||No||Yes||The examiner places a pachymeter gently on the front of the eye to measure its thickness.|
|Nerve fiber analysis||Thickness of the nerve fiber layer||Maybe||Maybe||Using one of several techniques, the nerve fibers are examined.|
Glaucoma has been classified into specific types:
Primary glaucoma and its variants
Primary glaucoma (H40.1-H40.2)
- Primary open-angle glaucoma, also known as chronic open-angle glaucoma, chronic simple glaucoma, glaucoma simplex
- High-tension glaucoma
- Low-tension glaucoma
- Primary angle closure glaucoma, also known as primary closed-angle glaucoma, narrow-angle glaucoma, pupil-block glaucoma, acute congestive glaucoma
- Acute angle closure glaucoma (aka AACG)
- Chronic angle closure glaucoma
- Intermittent angle closure glaucoma
- Superimposed on chronic open-angle closure glaucoma ("combined mechanism" – uncommon)
Variants of primary glaucoma
- Pigmentary glaucoma
- Exfoliation glaucoma, also known as pseudoexfoliative glaucoma or glaucoma capsulare
- Primary juvenile glaucoma
Primary angle closure glaucoma is caused by contact between the iris and trabecular meshwork, which in turn obstructs outflow of the aqueous humor from the eye.
This contact between iris and trabecular meshwork (TM) may gradually damage the function of the meshwork until it fails to keep pace with aqueous production, and the pressure rises.
In over half of all cases, prolonged contact between iris and TM causes the formation of synechiae (effectively "scars").
These cause permanent obstruction of aqueous outflow.
In some cases, pressure may rapidly build up in the eye, causing pain and redness (symptomatic, or so-called "acute" angle closure).
In this situation, the vision may become blurred, and halos may be seen around bright lights.
Accompanying symptoms may include a headache and vomiting.
Diagnosis is made from physical signs and symptoms: pupils mid-dilated and unresponsive to light, cornea edematous (cloudy), reduced vision, redness, and pain.
However, the majority of cases are asymptomatic.
Prior to the very severe loss of vision, these cases can only be identified by examination, generally by an eye care professional.
Once any symptoms have been controlled, the first line (and often definitive) treatment is laser iridotomy.
This may be performed using either Nd:YAG or argon lasers, or in some cases by conventional incisional surgery.
The goal of treatment is to reverse and prevent contact between the iris and trabecular meshwork.
In early to moderately advanced cases, iridotomy is successful in opening the angle in around 75% of cases.
In the other 25%, laser iridoplasty, medication (pilocarpine) or incisional surgery may be required.
Primary open-angle glaucoma is when optic nerve damage results in a progressive loss of the visual field.
This is associated with increased pressure in the eye.
Not all people with primary open-angle glaucoma have eye pressure that is elevated beyond normal, but decreasing the eye pressure further has been shown to stop progression even in these cases.
The increased pressure is caused by trabecular meshwork blockage.
Because the microscopic passageways are blocked, the pressure builds up in the eye and causes imperceptible very gradual vision loss.
Peripheral vision is affected first, but eventually the entire vision will be lost if not treated.
Diagnosis is made by looking for cupping of the optic nerve.
Prostaglandin agonists work by opening uveoscleral passageways.
Beta-blockers, such as timolol, work by decreasing aqueous formation.
Carbonic anhydrase inhibitors decrease bicarbonate formation from ciliary processes in the eye, thus decreasing the formation of aqueous humor.
Parasympathetic analogs are drugs that work on the trabecular outflow by opening up the passageway and constricting the pupil.
Developmental glaucoma (Q15.0)
- Primary congenital glaucoma
- Infantile glaucoma
- Glaucoma associated with hereditary or familial diseases
Secondary glaucoma (H40.3-H40.6)
- Inflammatory glaucoma
- Uveitis of all types
- Fuchs heterochromic iridocyclitis
- Phacogenic glaucoma
- Angle-closure glaucoma with mature cataract
- Phacoanaphylactic glaucoma secondary to rupture of lens capsule
- Phacolytic glaucoma due to phacotoxic meshwork blockage
- Subluxation of lens
- Glaucoma secondary to intraocular hemorrhage
- Hemolytic glaucoma, also known as erythroclastic glaucoma
- Traumatic glaucoma
- Angle recession glaucoma: Traumatic recession on anterior chamber angle
- Postsurgical glaucoma
- Neovascular glaucoma (see below for more details)
- Drug-induced glaucoma
- Corticosteroid induced glaucoma
- Alpha-chymotrypsin glaucoma. Postoperative ocular hypertension from use of alpha chymotrypsin.
- Glaucoma of miscellaneous origin
- Associated with intraocular tumors
- Associated with retinal detachments
- Secondary to severe chemical burns of the eye
- Associated with essential iris atrophy
- Toxic glaucoma
Neovascular glaucoma, an uncommon type of glaucoma, is difficult or nearly impossible to treat, and is often caused by proliferative diabetic retinopathy (PDR) or central retinal vein occlusion (CRVO).
Individuals with poor blood flow to the eye are highly at risk for this condition.
Neovascular glaucoma results when new, abnormal vessels begin developing in the angle of the eye that begin blocking the drainage.
Patients with such condition begin to rapidly lose their eyesight.
Sometimes, the disease appears very rapidly, especially after cataract surgery procedures.
A new treatment for this disease, as first reported by Kahook and colleagues, involves the use of a novel group of medications known as anti-VEGF agents.
These injectable medications can lead to a dramatic decrease in new vessel formation and, if injected early enough in the disease process, may lead to normalization of intraocular pressure.
Currently, there are no high-quality controlled trials demonstrating a beneficial effect of anti-VEGF treatments in lowering IOP in people with neovascular glaucoma.
Toxic glaucoma is open-angle glaucoma with an unexplained significant rise of intraocular pressure following unknown pathogenesis.
Intraocular pressure can sometimes reach 80 mmHg (11 kPa).
It characteristically manifests as ciliary body inflammation and massive trabecular oedema that sometimes extends to Schlemm's canal.
This condition is differentiated from malignant glaucoma by the presence of a deep and clear anterior chamber and a lack of aqueous misdirection.
Also, the corneal appearance is not as hazy.
A reduction in visual acuity can occur followed neuroretinal breakdown.
Associated factors include inflammation, drugs, trauma and intraocular surgery, including cataract surgery and vitrectomy procedures.
Gede Pardianto (2005) reported on four patients who had toxic glaucoma.
One of them underwent phacoemulsification with small particle nucleus drops.
Some cases can be resolved with some medication, vitrectomy procedures or trabeculectomy.
Valving procedures can give some relief, but further research is required.
Absolute glaucoma (H44.5) is the end stage of all types of glaucoma.
Severe pain is present in the eye.
The treatment of absolute glaucoma is a destructive procedure like cyclocryoapplication, cyclophotocoagulation, or injection of 99% alcohol.
Main article: Glaucoma medication
Intraocular pressure can be lowered with medication, usually eye drops.
Several classes of medications are used to treat glaucoma, with several medications in each class.
Each of these medicines may have local and systemic side effects.
Adherence to medication protocol can be confusing and expensive; if side effects occur, the patient must be willing either to tolerate them or to communicate with the treating physician to improve the drug regimen.
Initially, glaucoma drops may reasonably be started in either one or in both eyes.
Wiping the eye with an absorbent pad after the administration of eye drops may result in fewer adverse effects, like the growth of eyelashes and hyperpigmentation in the eyelid.
Poor compliance with medications and follow-up visits is a major reason for vision loss in glaucoma patients.
A 2003 study of patients in an HMO found half failed to fill their prescriptions the first time, and one-quarter failed to refill their prescriptions a second time.
Patient education and communication must be ongoing to sustain successful treatment plans for this lifelong disease with no early symptoms.
The possible neuroprotective effects of various topical and systemic medications are also being investigated.
- Prostaglandin analogs, such as latanoprost, bimatoprost and travoprost, increase uveoscleral outflow of aqueous humor. Bimatoprost also increases trabecular outflow.
- Topical beta-adrenergic receptor antagonists, such as timolol, levobunolol, and betaxolol, decrease aqueous humor production by the epithelium of the ciliary body.
- Alpha2-adrenergic agonists, such as brimonidine and apraclonidine, work by a dual mechanism, decreasing aqueous humor production and increasing uveoscleral outflow.
- Less-selective alpha agonists, such as epinephrine, decrease aqueous humor production through vasoconstriction of ciliary body blood vessels, useful only in open-angle glaucoma. Epinephrine's mydriatic effect, however, renders it unsuitable for closed-angle glaucoma due to further narrowing of the uveoscleral outflow (i.e. further closure of trabecular meshwork, which is responsible for absorption of aqueous humor).
- Miotic agents (parasympathomimetics), such as pilocarpine, work by contraction of the ciliary muscle, opening the trabecular meshwork and allowing increased outflow of the aqueous humour. Echothiophate, an acetylcholinesterase inhibitor, is used in chronic glaucoma.
- Carbonic anhydrase inhibitors, such as dorzolamide, brinzolamide, and acetazolamide, lower secretion of aqueous humor by inhibiting carbonic anhydrase in the ciliary body.
Argon laser trabeculoplasty (ALT) may be used to treat open-angle glaucoma, but this is a temporary solution, not a cure.
A 50-μm argon laser spot is aimed at the trabecular meshwork to stimulate the opening of the mesh to allow more outflow of aqueous fluid.
Usually, half of the angle is treated at a time.
Traditional laser trabeculoplasty uses a thermal argon laser in an argon laser trabeculoplasty procedure.
Nd:YAG laser peripheral iridotomy (LPI) may be used in patients susceptible to or affected by angle closure glaucoma or pigment dispersion syndrome.
During laser iridotomy, laser energy is used to make a small, full-thickness opening in the iris to equalize the pressure between the front and back of the iris, thus correcting any abnormal bulging of the iris.
In people with narrow angles, this can uncover the trabecular meshwork.
In some cases of intermittent or short-term angle closure, this may lower the eye pressure.
Laser iridotomy reduces the risk of developing an attack of acute angle closure.
In most cases, it also reduces the risk of developing chronic angle closure or of adhesions of the iris to the trabecular meshwork.
Diode laser cycloablation lowers IOP by reducing aqueous secretion by destroying secretory ciliary epithelium.
Main article: Glaucoma surgery
Both laser and conventional surgeries are performed to treat glaucoma.
Surgery is the primary therapy for those with congenital glaucoma.
Generally, these operations are a temporary solution, as there is not yet a cure for glaucoma.
Canaloplasty is a nonpenetrating procedure using microcatheter technology.
To perform a canaloplasty, an incision is made into the eye to gain access to the Schlemm's canal in a similar fashion to a viscocanalostomy.
A microcatheter will circumnavigate the canal around the iris, enlarging the main drainage channel and its smaller collector channels through the injection of a sterile, gel-like material called viscoelastic.
The catheter is then removed and a suture is placed within the canal and tightened.
By opening the canal, the pressure inside the eye may be relieved, although the reason is unclear, since the canal (of Schlemm) does not have any significant fluid resistance in glaucoma or healthy eyes.
Long-term results are not available.
The most common conventional surgery performed for glaucoma is the trabeculectomy.
Here, a partial thickness flap is made in the scleral wall of the eye, and a window opening is made under the flap to remove a portion of the trabecular meshwork.
The scleral flap is then sutured loosely back in place to allow fluid to flow out of the eye through this opening, resulting in lowered intraocular pressure and the formation of a bleb or fluid bubble on the surface of the eye.
Scarring can occur around or over the flap opening, causing it to become less effective or lose effectiveness altogether.
Traditionally, chemotherapeutic adjuvants, such as mitomycin C (MMC) or 5-fluorouracil (5-FU), are applied with soaked sponges on the wound bed to prevent filtering blebs from scarring by inhibiting fibroblast proliferation.
Contemporary alternatives to prevent the scarring of the meshwork opening include the sole or combinative implementation of nonchemotherapeutic adjuvants such as the Ologen collagen matrix, which has been clinically shown to increase the success rates of surgical treatment.
Collagen matrix prevents scarring by randomizing and modulating fibroblast proliferation in addition to mechanically preventing wound contraction and adhesion.
Glaucoma drainage implants
Main article: Glaucoma valve
The first glaucoma drainage implant was developed in 1966.
Since then, several types of implants have followed on from the original: the Baerveldt tube shunt, or the valved implants, such as the Ahmed glaucoma valve implant or the ExPress Mini Shunt and the later generation pressure ridge Molteno implants.
These are indicated for glaucoma patients not responding to maximal medical therapy, with previous failed guarded filtering surgery (trabeculectomy).
The flow tube is inserted into the anterior chamber of the eye, and the plate is implanted underneath the conjunctiva to allow a flow of aqueous fluid out of the eye into a chamber called a bleb.
- The first-generation Molteno and other nonvalved implants sometimes require the ligation of the tube until the bleb formed is mildly fibrosed and water-tight. This is done to reduce postoperative hypotony—sudden drops in postoperative intraocular pressure.
- Valved implants, such as the Ahmed glaucoma valve, attempt to control postoperative hypotony by using a mechanical valve.
- Ab interno implants, such as the Xen Gel Stent, are transscleral implants by an ab interno procedure to channel aqueous humor into the non-dissected Tenon's space, creating a subconjunctival drainage area similar to a bleb. The implants are transscleral and different from other ab interno implants that do not create a transscleral drainage, such as iStent, CyPass, or Hydrus.
The ongoing scarring over the conjunctival dissipation segment of the shunt may become too thick for the aqueous humor to filter through.
This may require preventive measures using antifibrotic medications, such as 5-fluorouracil or mitomycin-C (during the procedure), or other nonantifibrotic medication methods, such as collagen matrix implant, or biodegradable spacer, or later on create a necessity for revision surgery with the sole or combinative use of donor patch grafts or collagen matrix implant.
And for glaucomatous painful blind eye and some cases of glaucoma, cyclocryotherapy for ciliary body ablation could be considered to be performed.
Laser-assisted nonpenetrating deep sclerectomy
The most common surgical approach currently used for the treatment of glaucoma is trabeculectomy, in which the sclera is punctured to alleviate intraocular pressure.
Nonpenetrating deep sclerectomy (NPDS) surgery is a similar, but modified, procedure, in which instead of puncturing the scleral bed and trabecular meshwork under a scleral flap, a second deep scleral flap is created, excised, with further procedures of deroofing the Schlemm's canal, upon which, percolation of liquid from the inner eye is achieved and thus alleviating intraocular pressure, without penetrating the eye.
NPDS is demonstrated to have significantly fewer side effects than trabeculectomy.
However, NPDS is performed manually and requires higher level of skills that may be assisted with instruments.
In order to prevent wound adhesion after deep scleral excision and to maintain good filtering results, NPDS as with other non-penetrating procedures is sometimes performed with a variety of biocompatible spacers or devices, such as the Aquaflow collagen wick, ologen Collagen Matrix, or Xenoplast glaucoma implant.
Laser-assisted NPDS is performed with the use of a CO2 laser system.
The laser-based system is self-terminating once the required scleral thickness and adequate drainage of the intraocular fluid have been achieved.
This self-regulation effect is achieved as the CO2 laser essentially stops ablating as soon as it comes in contact with the intraocular percolated liquid, which occurs as soon as the laser reaches the optimal residual intact layer thickness.
In open-angle glaucoma, the typical progression from normal vision to complete blindness takes about 25 years to 70 years without treatment, depending on the method of estimation used.
The intraocular pressure can also have an effect, with higher pressures reducing the time until blindness.
As of 2010, there were 44.7 million people in the world with open angle glaucoma.
The same year, there were 2.8 million people in the United States with open angle glaucoma.
By 2020, the prevalence is projected to increase to 58.6 million worldwide and 3.4 million in the United States.
Both internationally and in the United States, glaucoma is the second-leading cause of blindness.
Globally, cataracts are a more common cause.
Glaucoma is also the leading cause of blindness in African Americans, who have higher rates of primary open-angle glaucoma.
Bilateral vision loss can negatively affect mobility and interfere with driving.
The association of elevated intraocular pressure (IOP) and glaucoma was first described by Englishman Richard Bannister in 1622: "...that the Eye be grown more solid and hard, then naturally it should be...".
Angle-closure glaucoma was treated with cataract extraction by John Collins Warren in Boston as early as 1806.
The invention of the ophthalmoscope by Hermann Helmholtz in 1851 enabled ophthalmologists for the first time to identify the pathological hallmark of glaucoma, the excavation of the optic nerve head due to retinal ganglion cell loss.
The first reliable instrument to measure intraocular pressure was invented by Norwegian ophthalmologist Hjalmar August Schiøtz in 1905.
About half a century later, Hans Goldmann in Berne, Switzerland, developed his applanation tonometer which still today - despite numerous new innovations in diagnostics - is considered the gold standard of determining this crucial pathogenic factor.
In the late 20th century, further pathomechanisms beyond elevated IOP were discovered and became the subject of research like insufficient blood supply – often associated with low or irregular blood pressure – to the retina and optic nerve head.
The first drug to reduce IOP, pilocarpine, was introduced in the 1870s; other major innovations in pharmacological glaucoma therapy were the introduction of beta blocker eye drops in the 1970s and of prostaglandin analogues and topical (locally administered) carbonic anhydrase inhibitors in the mid-1990s..
Early surgical techniques like iridectomy and fistulating methods have recently been supplemented by less invasive procedures like small implants, a range of options now widely called MIGS (micro-invasive glaucoma surgery).
The word "glaucoma" comes from the Ancient Greek γλαύκωμα, a derivative of γλαυκóς, which commonly described the color of eyes which were not dark (i.e. blue, green, light gray).
Eyes described as γλαυκóς due to disease might have had a gray cataract in the Hippocratic era, or, in the early Common Era, the greenish pupillary hue sometimes seen in angle-closure glaucoma.
Rho kinase inhibitors
More compounds in this class are being investigated in phase 2 and phase 3 trials.
A 2013 Cochrane Systematic Review compared the effect of brimonidine and timolol in slowing the progression of open angle glaucoma in adult participants.
The results showed that participants assigned to brimonidine showed less visual field progression than those assigned to timolol, though the results were not significant, given the heavy loss-to-followup and limited evidence.
The mean intraocular pressures for both groups were similar.
Participants in the brimonidine group had a higher occurrence of side effects caused by medication than participants in the timolol group.
Studies in the 1970s reported that the use of cannabis may lower intraocular pressure.
In an effort to determine whether marijuana, or drugs derived from it, might be effective as a glaucoma treatment, the US National Eye Institute supported research studies from 1978 to 1984.
These studies demonstrated some derivatives of marijuana lowered intraocular pressure when administered orally, intravenously, or by smoking, but not when topically applied to the eye.
In 2003, the American Academy of Ophthalmology released a position statement stating that cannabis was not more effective than prescription medications.
Furthermore, no scientific evidence has been found that demonstrates increased benefits and/or diminished risks of cannabis use to treat glaucoma compared with the wide variety of pharmaceutical agents now available.
In 2010 the American Glaucoma Society published a position paper discrediting the use of cannabis as a legitimate treatment for elevated intraocular pressure, for reasons including short duration of action and side effects that limit many activities of daily living.
Credits to the contents of this page go to the authors of the corresponding Wikipedia page: en.wikipedia.org/wiki/Glaucoma.